T J Daskivich1, L Kwan2, A Dash3, M S Litwin4. 1. 1] Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA [2] Greater Los Angeles Veterans Affairs Medical Center, Los Angeles, CA, USA. 2. Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA. 3. Department of Urology, University of Washington, Seattle, Washington, USA. 4. 1] Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA [2] Greater Los Angeles Veterans Affairs Medical Center, Los Angeles, CA, USA [3] Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA [4] Department of Health Policy & Management, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA.
Abstract
BACKGROUND: African-American men with prostate cancer typically have higher tumor risk at diagnosis, lower rates of surgical treatment and poorer cancer-specific survival compared with Caucasians. Receipt of care within the Veterans Affairs (VA) healthcare system may reduce barriers that influence these disparities. METHODS: We sampled 1258 men with nonmetastatic prostate cancer diagnosed at the Greater Los Angeles and Long Beach VA Medical Centers between 1998 and 2004. We compared African Americans and Caucasians with respect to tumor characteristics using ordinal logistic regression, treatment choice across substrata of tumor risk using logistic regression, and cancer-specific and other-cause mortality using competing risks regression analysis. RESULTS: Multivariate ordinal logistic regression revealed no significant differences in odds of higher tumor risk (odds ratio (OR) 1.22, 95% confidence interval (CI) 0.98-1.53, P=0.08), Gleason score (OR 0.90, 95% CI 0.7-1.16, P=0.4) or clinical stage (OR 1.04, 95% CI 0.79-1.38, P=0.8) for African Americans compared with Caucasians. African-American men had similar odds of aggressive treatment as did Caucasians for low-risk (OR 0.92, 95% CI 0.57-1.53, P=0.8), intermediate-risk (OR 0.75, 95% CI 0.44-1.26, P=0.3) and high-risk disease (OR 0.87, 95% CI 0.52-1.44, P=0.6). In competing risks regression analysis, African Americans had a lower but nonsignificant hazard of cancer-specific mortality compared with Caucasians (sub-hazard ratio 0.6, 95% CI 0.28-1.26, P=0.2) and nearly identical risk of other-cause mortality (sub-hazard ratio 0.98, 95% CI 0.78-1.22, P=0.8). CONCLUSIONS: We found no significant differences in tumor burden, treatment choice or survival outcomes between African Americans and Caucasians cared for in the equal-access VA Healthcare setting.
BACKGROUND: African-American men with prostate cancer typically have higher tumor risk at diagnosis, lower rates of surgical treatment and poorer cancer-specific survival compared with Caucasians. Receipt of care within the Veterans Affairs (VA) healthcare system may reduce barriers that influence these disparities. METHODS: We sampled 1258 men with nonmetastatic prostate cancer diagnosed at the Greater Los Angeles and Long Beach VA Medical Centers between 1998 and 2004. We compared African Americans and Caucasians with respect to tumor characteristics using ordinal logistic regression, treatment choice across substrata of tumor risk using logistic regression, and cancer-specific and other-cause mortality using competing risks regression analysis. RESULTS: Multivariate ordinal logistic regression revealed no significant differences in odds of higher tumor risk (odds ratio (OR) 1.22, 95% confidence interval (CI) 0.98-1.53, P=0.08), Gleason score (OR 0.90, 95% CI 0.7-1.16, P=0.4) or clinical stage (OR 1.04, 95% CI 0.79-1.38, P=0.8) for African Americans compared with Caucasians. African-American men had similar odds of aggressive treatment as did Caucasians for low-risk (OR 0.92, 95% CI 0.57-1.53, P=0.8), intermediate-risk (OR 0.75, 95% CI 0.44-1.26, P=0.3) and high-risk disease (OR 0.87, 95% CI 0.52-1.44, P=0.6). In competing risks regression analysis, African Americans had a lower but nonsignificant hazard of cancer-specific mortality compared with Caucasians (sub-hazard ratio 0.6, 95% CI 0.28-1.26, P=0.2) and nearly identical risk of other-cause mortality (sub-hazard ratio 0.98, 95% CI 0.78-1.22, P=0.8). CONCLUSIONS: We found no significant differences in tumor burden, treatment choice or survival outcomes between African Americans and Caucasians cared for in the equal-access VA Healthcare setting.
Authors: Vickie L Shavers; Martin L Brown; Arnold L Potosky; Carrie N Klabunde; W W Davis; Judd W Moul; Angela Fahey Journal: J Gen Intern Med Date: 2004-02 Impact factor: 5.128
Authors: Willie Underwood; James Jackson; John T Wei; Rodney Dunn; Edmond Baker; Sonya Demonner; David P Wood Journal: Cancer Date: 2005-02-01 Impact factor: 6.860
Authors: Brandon A Mahal; David R Ziehr; Ayal A Aizer; Andrew S Hyatt; Jesse D Sammon; Marianne Schmid; Toni K Choueiri; Jim C Hu; Christopher J Sweeney; Clair J Beard; Anthony V D'Amico; Neil E Martin; Christopher Lathan; Simon P Kim; Quoc-Dien Trinh; Paul L Nguyen Journal: Urol Oncol Date: 2014-05-17 Impact factor: 3.498
Authors: David I Chu; Daniel M Moreira; Leah Gerber; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland Journal: Cancer Date: 2012-03-13 Impact factor: 6.860
Authors: Stephen A Boorjian; R Jeffrey Karnes; Laureano J Rangel; Eric J Bergstralh; Michael L Blute Journal: J Urol Date: 2008-03-04 Impact factor: 7.450
Authors: Richard M Hoffman; Linda C Harlan; Carrie N Klabunde; Frank D Gilliland; Robert A Stephenson; William C Hunt; Arnold L Potosky Journal: J Gen Intern Med Date: 2003-10 Impact factor: 5.128
Authors: Robert Steven Gerhard; Dattatraya Patil; Yuan Liu; Kenneth Ogan; Mehrdad Alemozaffar; Ashesh B Jani; Omer N Kucuk; Viraj A Master; Theresa W Gillespie; Christopher P Filson Journal: Urol Oncol Date: 2017-01-12 Impact factor: 3.498
Authors: Kim Peterson; Johanna Anderson; Erin Boundy; Lauren Ferguson; Ellen McCleery; Kallie Waldrip Journal: Am J Public Health Date: 2018-03 Impact factor: 9.308
Authors: Mohamed H Kamel; Milan Bimali; Mahmoud I Khalil; Ehab Eltahawy; LJoseph Su; Nabil K Bissada; Rodney Davis Journal: Int Urol Nephrol Date: 2019-03-06 Impact factor: 2.370
Authors: Leanne Woods-Burnham; Laura Stiel; Shannalee R Martinez; Evelyn S Sanchez-Hernandez; Herbert C Ruckle; Frankis G Almaguel; Mariana C Stern; Lisa R Roberts; David R Williams; Susanne Montgomery; Carlos A Casiano Journal: Cancer Health Disparities Date: 2020
Authors: Eric T Miller; Karim Chamie; Lorna Kwan; Michael S Lewis; Beatrice S Knudsen; Isla P Garraway Journal: Cancer Med Date: 2016-12-20 Impact factor: 4.452
Authors: Michelle S Wong; Katherine J Hoggatt; W Neil Steers; Susan M Frayne; Alexis K Huynh; Elizabeth M Yano; Fay S Saechao; Boback Ziaeian; Donna L Washington Journal: Health Equity Date: 2019-04-08